Mimickers & Differential Diagnosis of Multiple Sclerosis
Misdiagnosis of multiple sclerosis (MS) remains a significant clinical problem, estimated at 10–15% even at MS specialty centers. The expanded sensitivity of modern diagnostic criteria, combined with the proliferation of immunosuppressive therapies, has increased the stakes of diagnostic accuracy. MS is a diagnosis of exclusion — the 2024 McDonald criteria explicitly require that "no better explanation" exists for the clinical presentation. A systematic approach to MS mimickers is essential for avoiding both underdiagnosis and misdiagnosis.
Bottom Line
- Misdiagnosis rate: Estimated 10–15% at MS centers; the true prevalence is unknown
- Top mimickers: Migraine, small vessel ischemic disease, NMOSD, MOGAD, neurosarcoidosis, CNS vasculitis
- Key differentiators from NMOSD: AQP4-Ab positivity, longitudinally extensive transverse myelitis (≥3 segments), area postrema syndrome, bilateral optic neuritis
- Key differentiators from MOGAD: MOG-Ab positivity, bilateral or recurrent optic neuritis, ADEM-like presentation, conus/lower cord predilection
- Red flag mnemonics: MIMICS (MRI red flags) and clinical red flags guide when to pursue additional workup
- Central vein sign (CVS) can discriminate 87% of misdiagnosed MS patients and is particularly helpful against vascular and migraine mimics
- Always test for AQP4-Ab and MOG-Ab in optic neuritis with poor recovery, LETM, and area postrema syndrome
Scope of Misdiagnosis
Misdiagnosis of MS has substantial personal, medical, professional, and societal repercussions. Patients may be exposed to unnecessary immunosuppressive therapies with significant side effects, while the actual underlying condition goes untreated. Studies at academic MS centers have demonstrated that patients are frequently referred with an incorrect MS diagnosis, sometimes after years of inappropriate treatment.
Common reasons for misdiagnosis include:
- Over-reliance on nonspecific MRI white matter changes (especially in patients with migraine or vascular risk factors)
- Applying McDonald criteria to patients with atypical clinical presentations
- Insufficient workup for alternative diagnoses before initiating DMTs
- Limited validation of McDonald criteria in certain populations (older adults, ethnically diverse groups)
Major Categories of MS Mimickers
Inflammatory/Autoimmune Mimickers
| Condition | Key Features Distinguishing from MS | Diagnostic Tests |
|---|---|---|
| NMOSD | Longitudinally extensive TM (≥3 segments); bilateral or severe ON with poor recovery; area postrema syndrome (intractable nausea/vomiting/hiccups); brain lesions in periependymal/hypothalamic regions | AQP4-IgG (cell-based assay) |
| MOGAD | Bilateral or recurrent ON; ADEM-like presentations (esp. in children); fluffy, ill-defined brain lesions; conus/lower cord predilection; often cortical lesions; better recovery pattern | MOG-IgG (cell-based assay) |
| Neurosarcoidosis | Meningeal enhancement; cranial neuropathies (especially facial nerve); hypothalamic/pituitary involvement; longitudinally extensive spinal cord lesions; systemic features | ACE, chest imaging, PET, tissue biopsy, CSF (elevated protein, pleocytosis) |
| CNS vasculitis | Headache, encephalopathy, stroke-like episodes; lesions crossing vascular territories; meningeal/vessel wall enhancement; CSF pleocytosis | ESR, CRP, ANCA, vessel wall MRI, conventional angiography, brain biopsy |
| Neuro-Behçet disease | Oral/genital ulcers, uveitis; brainstem/diencephalic lesions; dural sinus thrombosis; positive pathergy test | Clinical criteria, HLA-B51 |
| Neuro-SLE | Multisystem involvement; longitudinally extensive myelitis; cerebritis; white matter lesions often subcortical | ANA, dsDNA, complement levels, antiphospholipid antibodies |
| Neuro-Sjögren | Sicca symptoms (dry eyes/mouth); peripheral neuropathy; dorsal root ganglionopathy; longitudinally extensive myelitis | SSA/SSB antibodies, Schirmer test, lip biopsy |
| IgG4-related disease | Pachymeningitis; orbital pseudotumor; cranial nerve palsies; multi-organ involvement | Serum IgG4 levels, tissue biopsy |
Vascular Mimickers
Small Vessel Ischemic Disease vs MS
- Periventricular white matter lesions are not specific to MS and occur commonly in small vessel ischemic disease, particularly in patients ≥50 years with vascular risk factors
- Increasing the threshold to ≥3 periventricular lesions helps distinguish MS from migraine but does NOT improve specificity against age-related changes
- Cortical/juxtacortical and periventricular regions are simultaneously affected in up to one-third of migraine patients
- Spinal cord lesions are generally NOT found in patients with cerebrovascular disease — a key differentiator
- CVS on susceptibility-weighted MRI can differentiate MS from vascular white matter disease
- CSF oligoclonal bands or kFLC index are helpful across all age groups
Migraine is one of the most common causes of MS misdiagnosis, as periventricular and subcortical white matter lesions can be found in up to 40% of migraine patients. Headache disorders should be carefully excluded before attributing white matter lesions to MS, especially in patients without typical clinical attacks.
Infectious Mimickers
| Infection | Key Features |
|---|---|
| Neurosyphilis | CSF VDRL, FTA-ABS; meningitis, cranial neuropathies, tabes dorsalis, general paresis |
| Neuroborreliosis (Lyme) | Cranial neuropathy (esp. facial), radiculopathy, meningitis; serology and CSF antibody index |
| Progressive multifocal leukoencephalopathy (PML) | JC virus; immunosuppression context; asymmetric white matter lesions not enhancing, no mass effect; PCR in CSF |
| HIV-associated myelopathy | Vacuolar myelopathy; progressive spastic paraparesis; HIV testing |
| HTLV-1 myelopathy (HAM/TSP) | Progressive spastic paraparesis; endemic areas; HTLV-1 serology |
| Tuberculosis | Basal meningitis; tuberculomas; pachymeningitis; endemic areas |
Metabolic and Genetic Mimickers
| Condition | Key Features |
|---|---|
| Vitamin B12 deficiency | Subacute combined degeneration; posterior column dysfunction; macrocytic anemia; elevated methylmalonic acid |
| Copper deficiency | Myelopathy mimicking B12 deficiency; history of zinc supplementation or bariatric surgery |
| Leber hereditary optic neuropathy (LHON) | Bilateral sequential painless visual loss; young males; mitochondrial DNA mutations |
| Leukodystrophies (adult-onset) | Adrenoleukodystrophy, metachromatic leukodystrophy; symmetric confluent white matter changes; family history; VLCFA, arylsulfatase A |
| CADASIL | Migraine with aura, lacunar strokes, psychiatric symptoms; anterior temporal and external capsule lesions; NOTCH3 mutations |
| Susac syndrome | Triad: encephalopathy + branch retinal artery occlusions + sensorineural hearing loss; central callosal "snowball" lesions |
Neoplastic Mimickers
- CNS lymphoma — can present as enhancing periventricular lesions; may initially respond to steroids, mimicking MS relapse treatment
- Glioma — infiltrative lesions can be confused with tumefactive MS
- Paraneoplastic/autoimmune encephalitis — can produce white matter and gray matter lesions
Differentiating MS from NMOSD and MOGAD
Distinguishing MS from NMOSD and MOGAD is among the most critical differential diagnostic challenges. Incorrect classification leads to inappropriate treatment choices with potentially life-threatening consequences (e.g., some MS DMTs can worsen NMOSD). The 2024 McDonald criteria emphasize MRI and antibody testing as the most robust tools for differentiation.
| Feature | MS | NMOSD | MOGAD |
|---|---|---|---|
| Antibody | Negative for AQP4 and MOG | AQP4-IgG positive | MOG-IgG positive |
| Optic neuritis | Typically unilateral, good recovery | Often bilateral or severe; poor recovery; posterior/chiasmatic involvement | Often bilateral; perineural enhancement; anterior predominant; generally good recovery |
| Myelitis | Partial, short segment (<3 vertebral segments) | LETM (≥3 segments); central/H-sign on axial; often cervical | LETM common; conus/lower cord predilection; often with gray matter involvement |
| Brain MRI | Periventricular (Dawson fingers), juxtacortical, infratentorial; central vein sign; ovoid lesions | Periependymal; hypothalamic/diencephalic; area postrema; often nonspecific or normal | Fluffy, ill-defined lesions; cortical; deep gray matter; often ADEM-like in children |
| CSF OCBs | Present in ~90% | Present in ~20–30% | Present in ~10–15% |
| Course | Relapsing-remitting or progressive | Relapsing; progressive course is rare | Relapsing or monophasic; rarely progressive |
| Sex ratio (F:M) | ~3:1 | ~9:1 | ~1:1 (adults); slight male predominance (children) |
| Treatment overlap | MS DMTs effective | Some MS DMTs worsen NMOSD (interferon-β, fingolimod, natalizumab) | Some MS DMTs may worsen MOGAD; steroids and IVIG effective |
Systematic Diagnostic Approach
When to Suspect an MS Mimicker
Clinical Red Flags
- Age of onset ≥50 years or <10 years
- Prominent constitutional symptoms (fever, weight loss, rash)
- Hyperacute onset (<24 hours) or very gradual onset (months)
- Bilateral or severe optic neuritis with poor recovery
- Complete transverse myelopathy with bilateral motor/sensory involvement
- Intractable nausea, vomiting, or hiccups (area postrema syndrome)
- Encephalopathy, seizures, or rapid cognitive decline
- Prominent headache or meningism
- Family history of similar white matter disease or metabolic disorder
- History of vascular risk factors (hypertension, diabetes, smoking, hyperlipidemia)
MRI Red Flags (MIMICS)
- Meningeal enhancement
- Indistinct or increasing lesions
- Macrobleeds and microbleeds
- Infarcts
- Cavities; complete ring enhancement
- Symmetric lesions; sparing of U fibers; siderosis; spinal cord longitudinally extensive lesions (≥3 segments)
CSF Red Flags
- Absent oligoclonal bands (present in ~90% of MS; absence should prompt reconsideration)
- Pleocytosis >50 cells/mm3 (typical MS has <50; higher counts suggest infection, lymphoma, NMOSD)
- Protein >100 mg/dL (MS rarely causes this degree of elevation)
- Atypical cells (neutrophils, eosinophils, malignant cells)
Recommended Workup for Atypical Presentations
| Category | Tests |
|---|---|
| Antibody testing | AQP4-IgG, MOG-IgG (cell-based assays) |
| Autoimmune screen | ESR, CRP, ANA, ENA, ANCA, complement levels, antiphospholipid antibodies, ACE |
| Infectious screen | Syphilis (VDRL/FTA-ABS), Lyme (serology), HIV, HTLV-1, HSV/VZV PCR, tuberculosis testing |
| Metabolic/toxic | Vitamin B12, methylmalonic acid, copper, ceruloplasmin, folate |
| Genetic | LHON mitochondrial DNA mutations (if bilateral optic neuropathy), VLCFA (adrenoleukodystrophy) |
| CSF studies | Cell count, protein, glucose, oligoclonal bands, kFLC index, cytology, flow cytometry |
| Paraneoplastic panel | If encephalopathy, subacute cognitive decline, or atypical MRI patterns |
| Advanced imaging | Susceptibility-weighted MRI (CVS, PRL), vessel wall MRI, spinal MRA/DSA, PET |
Role of Advanced MRI Biomarkers in Differential Diagnosis
Central Vein Sign
The CVS can discriminate MS from its mimickers in approximately 87% of previously misdiagnosed patients. It is particularly useful in differentiating MS from:
- Small vessel ischemic disease
- Migraine-related white matter lesions
- CNS vasculitis
- NMOSD (lower CVS proportion)
Paramagnetic Rim Lesions
PRLs represent chronic active lesions and are highly specific for MS (composite specificity 98%). They are rarely found in other radiological mimics and may help reduce misdiagnosis in atypical presentations.
Special Populations at Higher Misdiagnosis Risk
Populations Requiring Additional Caution
- Age ≥50 years: Vascular white matter changes become increasingly common; additional confirmatory features strongly recommended (spinal cord lesion, positive CSF, CVS positivity)
- Patients with vascular risk factors: Hypertension, smoking, diabetes, hyperlipidemia, known macrovascular disease increase misdiagnosis risk
- Pediatric patients: MOGAD is more prevalent than MS in younger children; MOG-IgG testing strongly recommended in all children <12 years with CNS demyelination
- Non-White populations: Higher suspicion for NMOSD (higher prevalence in some populations); consider NMOSD and MOGAD in patients presenting with optic-spinal phenotype
References
- Oh J. Diagnosis of multiple sclerosis. Continuum (Minneap Minn). 2022;28(4):1006-1024.
- Montalban X, Lebrun-Frénay C, Oh J, et al. Diagnosis of multiple sclerosis: 2024 revisions of the McDonald criteria. Lancet Neurol. 2025;24:850-865.
- Solomon AJ, Bourdette DN, Cross AH, et al. The contemporary spectrum of multiple sclerosis misdiagnosis. Neurology. 2016;87(13):1393-1399.
- Geraldes R, Ciccarelli O, Barkhof F, et al. The current role of MRI in differentiating multiple sclerosis from its imaging mimics. Nat Rev Neurol. 2018;14(4):199-213.
- Brownlee WJ, Hardy TA, Fazekas F, Miller DH. Diagnosis of multiple sclerosis: progress and challenges. Lancet. 2017;389(10076):1336-1346.